The 1,3‐dipolar cycloaddition of the C ‐ t ‐butyloxycarbonyl‐ N ‐mannosyl‐nitrone 5 , formed in situ from the partially protected D ‐mannose‐oxime 3 and the glyoxylate 4 , to ethylene gave preferentially the (3 S )‐ N ‐glycosyl‐isoxazolidine 6 which was transformed into the 3‐isoxazolidine‐carboxylate ( L ‐5‐oxaproline ester) 12 and into some derivatives thereof. The ( S )‐configuration of 12 was proved by chemical correlation with a derivative of L ‐asparagine. The D ‐5‐oxaproline ester was obtained from the corresponding N ‐ribosyl‐nitrone 24 . Two protected dipeptides containing either C ‐terminal‐ ( 28 ) or N ‐terminal‐5‐oxaproline (= Opro) ( 30 ) were synthesized. Starting from 12 , the analogue 1 of captopril® ( 2 ) was prepared and its activity as an inhibitor of the angiotensin‐converting‐enzyme (ACE) was examined.
No takes yet. Share an insight, caveat, or question.
Vasella et al. (1983) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: